Brian Posner joins Anadys board
This article was originally published in Scrip
Anadys Pharmaceuticals, a pharma company developing drugs to treat hepatitis C, has appointed Brian Posner, a private investor and president of Point Rider Group, to its board of directors. He previously served as CEO and co-chief investment officer of ClearBridge Advisors, and is currently on the boards of Biogen Idec and Arch Capital Group.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.